CERo Therapeutics Holdings, Inc. - Common Stock CERO 深 滬
等待開盤 10-29 09:30:00 美东时间
1.88
0.000
0.00%
華盛通- 最 高1.90
- 今 開1.85
- 成交量 19.76万股
- 最 低 1.81
- 昨 收 1.88
- 總市值 72.59万
- 52周最高 895.40
- 市盈率 靜 --
- 換手率 51.17%
- 52周最低 1.81
- 委 比 -9.43%
- 總股本 38.61万
- 歷史最高 24760.00
- 量 比 0.35
- 振 幅 4.79%
- 歷史最低 1.81
- 每 手 1
- 風險率 111.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025
South San Francisco, Oct. 15, 2025 - CERo Therapeutics Holdings, Inc. announces that Chief Executive Officer Chris Ehrlich will participate in a stem cell therapy panel at the Maxim Growth Summit in New York City on October 22-23. The event will feature discussions on the future of stem cell therapies, with a focus on the innovative approaches being developed in the biotechnology sector. CERo, a leader in cellular immunotherapy, is advancing next...
10-15 12:30
CERo Therapeutics Enters Securities Purchase Agreement
The latest announcement is out from CERo Therapeutics Holdings ( ($CERO) ). CER...
10-14 21:28
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target
D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price target.
10-13 22:43
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
CERo Therapeutics has completed the first cohort of its Phase 1 clinical trial for CER-1236 in acute myeloid leukemia (AML) patients, observing consistent cell expansion without dose-limiting toxicities. The Dose Escalation Safety Committee has approved the initiation of Cohort 2 with an increased starting dose. The company also plans to provide an additional infusion to Cohort 1 patient based on encouraging pharmacokinetic data. CERo emphasizes ...
10-13 12:30
'CERo Therapeutics CEO: We're "open" to takeover offers'- Axios
https://www.axios.com/pro/biotech-deals/2025/10/10/cero-therapeutics-ceo-open-takeover-offers
10-11 02:12
Broadwind Receives $11M In New Tower Orders From A Leading Global Wind Turbine Manufacturer
CICERO, Ill., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Broadwind (NASDAQ:BWEN, or the "Company"))), a diversified precision manufacturer of specialized components and equipment serving global markets, today announced that the
10-09 06:01
CERo Therapeutics Doses Third Patient In Phase 1 AML Trial Of CER-1236
Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohortSOUTH SAN FRANCISCO, Calif, Sept. 22,
09-22 21:18
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort
<p>CERo Therapeutics Holdings, Inc. has dosed the third patient in the starting dose cohort of its Phase 1 clinical trial for CER-1236 in acute myeloid leukemia (AML). The company anticipates additional results from the second dosing of the second patient. Stephen Strickland, Jr., M.D., MSCI, commented on the milestone, highlighting the importance of the safety and pharmacokinetic data gathered. The Phase 1/1b study aims to evaluate the safety, t...
09-22 13:15
For The FY 2025, Broadwind Expects Revenues In A Range Of $145M To $155M
CICERO, Ill., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Broadwind (NASDAQ:BWEN, or the "Company"))), a diversified precision manufacturer of specialized components and equipment serving global markets, today announced the
09-11 04:22
